Endo International PLC (NASDAQ: ENDP) and Biodel (NASDAQ:ALBO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitabiliy, valuation, dividends and risk.
Risk and Volatility
Endo International PLC has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Biodel has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Institutional and Insider Ownership
93.0% of Endo International PLC shares are owned by institutional investors. Comparatively, 12.4% of Biodel shares are owned by institutional investors. 0.5% of Endo International PLC shares are owned by insiders. Comparatively, 22.3% of Biodel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Endo International PLC and Biodel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Endo International PLC||-82.93%||25.32%||6.90%|
This is a summary of current ratings and target prices for Endo International PLC and Biodel, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Endo International PLC||0||14||5||0||2.26|
Endo International PLC presently has a consensus price target of $16.76, suggesting a potential upside of 104.95%. Biodel has a consensus price target of $35.00, suggesting a potential upside of 46.81%. Given Endo International PLC’s higher possible upside, analysts plainly believe Endo International PLC is more favorable than Biodel.
Earnings and Valuation
This table compares Endo International PLC and Biodel’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Endo International PLC||$4.08 billion||0.45||$411.84 million||($15.20)||-0.54|
|Biodel||$11.24 million||13.35||-$10.33 million||N/A||N/A|
Endo International PLC has higher revenue and earnings than Biodel.
Endo International PLC beats Biodel on 7 of the 12 factors compared between the two stocks.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company’s subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.
Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with our FREE daily email newsletter.